Constellation Pharmaceuticals Stock Forecast, Price & News

Constellation Pharmaceuticals' stock was trading at $32.57 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, CNST shares have decreased by 45.9% and is now trading at $17.62.
View which stocks have been most impacted by COVID-19.

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Constellation Pharmaceuticals in the last year. There are currently 3 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Constellation Pharmaceuticals.

Constellation Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020.
View our earnings forecast for Constellation Pharmaceuticals.

Constellation Pharmaceuticals Inc (NASDAQ:CNST) posted its quarterly earnings data on Wednesday, August, 5th. The company reported ($0.70) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.64) by $0.06.
View Constellation Pharmaceuticals' earnings history.

10 equities research analysts have issued 12 month price targets for Constellation Pharmaceuticals' stock. Their forecasts range from $28.00 to $75.00. On average, they expect Constellation Pharmaceuticals' stock price to reach $46.56 in the next year. This suggests a possible upside of 164.2% from the stock's current price.
View analysts' price targets for Constellation Pharmaceuticals.

Constellation Pharmaceuticals saw a decline in short interest during the month of August. As of August 31st, there was short interest totaling 3,600,000 shares, a decline of 15.5% from the August 15th total of 4,260,000 shares. Based on an average daily trading volume, of 668,500 shares, the short-interest ratio is currently 5.4 days.
View Constellation Pharmaceuticals' Short Interest.

Some companies that are related to Constellation Pharmaceuticals include Legend Biotech (LEGN), Biohaven Pharmaceutical (BHVN), Reata Pharmaceuticals (RETA), ChemoCentryx (CCXI), Turning Point Therapeutics (TPTX), Amicus Therapeutics (FOLD), Nektar Therapeutics (NKTR), HYPERA S A/S (HYPMY), Insmed (INSM), Principia Biopharma (PRNB), Global Blood Therapeutics (GBT), Schrodinger (SDGR), TG Therapeutics (TGTX), SAGE Therapeutics (SAGE) and GW Pharmaceuticals PLC- (GWPH).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Constellation Pharmaceuticals investors own include Advanced Micro Devices (AMD), Inovio Pharmaceuticals (INO), Intel (INTC), AbbVie (ABBV), Applied Materials (AMAT), NVIDIA (NVDA), AT&T (T), Cisco Systems (CSCO), Johnson & Johnson (JNJ) and Novavax (NVAX).

(CNST) raised $80 million in an initial public offering (IPO) on Thursday, July 19th 2018. The company issued 5,300,000 shares at $14.00-$16.00 per share. J.P. Morgan, Jefferies and BMO Capital Markets acted as the underwriters for the IPO and Oppenheimer was co-manager.

Constellation Pharmaceuticals trades on the NASDAQ under the ticker symbol "CNST."

Constellation Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Great Point Partners LLC (7.33%), Vanguard Group Inc. (3.53%), Venrock Management V LLC (3.28%), Regents of The University of California (2.95%), Deerfield Management Company L.P. Series C (1.84%) and Victory Capital Management Inc. (1.82%). Company insiders that own Constellation Pharmaceuticals stock include Adrian Senderowicz, Anthony B Evnin, Emma Reeve, Group L P Column, James E Audia, Karen Valentine, Mark A Goldsmith, Of The University Of C Regents and Patrick Trojer.
View institutional ownership trends for Constellation Pharmaceuticals.

CNST stock was sold by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., FMR LLC, Regents of The University of California, Deerfield Management Company L.P. Series C, P.A.W. Capital Corp, Alps Advisors Inc., AQR Capital Management LLC, and Strs Ohio. Company insiders that have sold Constellation Pharmaceuticals company stock in the last year include Adrian Senderowicz, Emma Reeve, James E Audia, Karen Valentine, Mark A Goldsmith, Of The University Of C Regents, and Patrick Trojer.
View insider buying and selling activity for Constellation Pharmaceuticals.

CNST stock was purchased by a variety of institutional investors in the last quarter, including Venrock Management V LLC, Great Point Partners LLC, Vanguard Group Inc., Jennison Associates LLC, Candriam Luxembourg S.C.A., Goldman Sachs Group Inc., Sofinnova Investments Inc., and Venrock Partners Management V LLC. Company insiders that have bought Constellation Pharmaceuticals stock in the last two years include Anthony B Evnin, and Group L P Column.
View insider buying and selling activity for Constellation Pharmaceuticals.

Shares of CNST can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of CNST stock can currently be purchased for approximately $17.62.

Constellation Pharmaceuticals has a market capitalization of $836.95 million. The company earns $-85,550,000.00 in net income (profit) each year or ($3.04) on an earnings per share basis. Constellation Pharmaceuticals employs 82 workers across the globe.

The official website for Constellation Pharmaceuticals is www.constellationpharma.com.

Constellation Pharmaceuticals' mailing address is 215 FIRST STREET SUITE 200, CAMBRIDGE MA, 02142. The company can be reached via phone at 617-714-0555 or via email at [email protected]